TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04883229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halo Neuroscience Neurostimulator
Description: Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks.
Study: NCT06375512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ Vaccine (IN001)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ Vaccine (IN001)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ Vaccine (IN001)
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Sterile suspension for injection
Study: NCT04728893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Nemtabrutinib tablets administered PO QD.
Study: NCT05253131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: * Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer.
Study: NCT05715125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose A VTX958
Description: Dose A VTX958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose B VTX958
Description: Dose B VTX958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05328154

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care
Description: * Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0 and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Follow-up diary to be completed at months 1 and 12 of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation
Description: * Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0; Visit 2: Day 0+9 months and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Magnesium intake for 1 period of 3 months~* Phone call~* Follow-up diary to be completed at months 1, 10, 11 and 12 of the study
Study: NCT06145412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapan
Description: Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam
Description: 60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
Study: NCT05382559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3082
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3082
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3082
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3082
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3082
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaplatin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous Infusion
Study: NCT05633823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Game Training
Description: Mobile application game training can be used interactively with smartphones and tablets.~* A user account will be created after the application is downloaded to the mobile phone/tablet.~* After logging into the application, the map of the game will be displayed.~* The game will start with the first level of the game consisting of 5 levels.~* At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~* After watching the videos, interactive games will be played.~* Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~* After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished.
Study: NCT04979468

Intervention type: DRUG
Group type: OTHER
Intervention: DOVATO
Description: Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).

Intervention type: DRUG
Group type: OTHER
Intervention: DOVATO
Description: Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Study: NCT04965467

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for Fabry disease
Description: A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
Study: NCT05725889

Intervention type: DEVICE
Intervention: recation time test
Description: visual-finger tapping and auditory reaction time tests

Intervention type: DEVICE
Intervention: recation time test
Description: visual-finger tapping and auditory reaction time tests
Study: NCT06189391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN201
Description: In fixed dosing group, patients will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks, followed by 1 week off for 4 weeks as a treatment cycle.~Patients in step-up dosing group will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks (without treatment off week). Patients who complete 4 treatment cycles and remain in complete response (CR) or partial response (PR) may also be considered by the investigator for 2-weekly dosing (Q2W, window: -3 days, 4 weeks in a treatment cycle), which allows further comparative observation of the long-term efficacy and safety of Q2W. Treatment will be continued untill confirmed disease progression, intolerable toxicity, withdrawal of consent, patient being lost to follow-up, receipt of other antitumor therapy, death or study termination by sponsor, whichever occurs earlier, or up to 12 months in the absence of disease progression.
Study: NCT06245200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UNIPDES - Internet Based Intervention - GUIDED
Description: The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones). Participants in this arm will receive weekly feedback from counselors through the web software used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UNIPDES - Internet Based Intervention - UNGUIDED
Description: The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones).
Study: NCT06358066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: self assembling peptide p11-4 with fluoride
Description: Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% sodium fluoride varnish
Description: Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
Study: NCT05382559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound-paclitaxel
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous Infusion
Study: NCT05702645

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Patients undergo saliva/buccal and blood sample collection

Intervention type: OTHER
Intervention: Clinical Evaluation
Description: Undergo a clinical assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05740449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal chemotherapy
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Study: NCT05137119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin
Description: benzylpenicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin or Daptomycin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effectiveness of early switch to oral antibiotics
Description: This involves testing a strategy rather than individual antibiotic agents

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole body FDG PET/CT Imaging
Description: Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
Study: NCT06219616

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BKV immune monitoring
Description: Blood will be drawn and investigated for BKV-specific T cell response.
Study: NCT06552598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD01(the recombinant oncolytic adenovirus)
Description: Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged.
Study: NCT06156319

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05702645

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06554912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic Decompression
Description: Patients will be prepared according to standard procedures Clinical examinations, para-clinical assessment and biological tests Patient will be set in angiography room and local anesthesia at the puncture area (femoral vein or brachial vein).~Obtain access to the femoral vein per standard procedures (option for brachial access depending on anatomy based on pre-operative CT, per physician discretion) After setting introducer sheath, catheterism of cardiac cavity will be performed for assess the following standard hemodynamic measures Catheterism of thoracic duct through the subclavian vein will be performed under fluoro guidance and phlebography using contrast Measure TD and central venous pressures Deploy stent under fluoro guidance Standard vascular stent deployed in subclavian vein and into lymphovenous junction Evaluate the procedure with standard phlebography and hemodynamic measures Remove catheters, and temporary compression as standard venous procedures
Study: NCT05290779

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: selective lumbar nerve root injection
Description: selective lumbar nerve root steroid injection for treatment of radicular pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective lumbar nerve root injection
Description: selective lumbar nerve root steroid injection for treatment of radicular pain.
Study: NCT06467565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan
Description: NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
Study: NCT05830604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal Splint Treatment- Non Invasive treatment
Description: Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal Splint Treatment- Non Invasive treatment
Description: Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
Study: NCT06116162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SVF-gel Filling and CO2 fractional laser
Description: SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVF-gel Filling and CO2 fractional laser
Description: SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage.
Study: NCT06183918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 3. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
Study: NCT04858009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given via HIPEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC with mitomycin and cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given via HIPEC
Study: NCT05967338

Intervention type: DEVICE
Intervention: using McGrath Video Laryngoscope
Description: glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope

Intervention type: DEVICE
Intervention: using McGrath Video Laryngoscope
Description: glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
Study: NCT06199440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group I
Description: First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
Study: NCT05780684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOX dose-escalation algorithm
Description: Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
Study: NCT04858009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT06199440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group II
Description: Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
Study: NCT04944082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: (The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
Study: NCT03829215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAERVest cooling device
Description: The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.